Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | EEF2K | O00418 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5392623 | 0.99 | MEN1 (0.49) | MEN1KMT2AAGTR2EEF2KKCNH2 | |
| SCHEMBL3648193 | 0.89 | L3MBTL1 (0.48) | MEN1KMT2AEEF2K | |
| SCHEMBL3645089 | 0.86 | AGTR2 (0.53) | AGTR2KCNH2 | |
| SCHEMBL5400769 | 0.81 | AGTR2 (0.53) | MEN1KMT2AAGTR2SIGMAR1TACR1 | |
| SCHEMBL5405775 | 0.81 | L3MBTL1 (0.48) | MEN1KMT2AEEF2KSIGMAR1BCHE | |
| SCHEMBL5397090 | 0.81 | TP53 (0.40) | MEN1KMT2AAGTR2EEF2KCHRM4 | |
| SCHEMBL5397096 | 0.81 | TP53 (0.40) | MEN1KMT2AAGTR2EEF2KCHRM4 | |
| SCHEMBL5391800 | 0.80 | TACR1 (0.41) | TACR1 | |
| SCHEMBL27784680 | 0.79 | DPP4 (0.48) | MEN1KMT2AAGTR2KCNH2SIGMAR1 | |
| SCHEMBL27784713 | 0.77 | AGTR2 (0.59) | MEN1KMT2AAGTR2KCNH2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778831-A | Novel piperazine amide derivatives | HOFFMANN LA ROCHE | 2010-07-14 | — | — | CN | disclosed |
| US-7214680-B2 | 2-substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| EP-1423117-B1 | 2-SUBSTITUTED 1-ARYLPIPERAZINES AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2005-10-19 | — | — | EP | disclosed |
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2004-12-02 | — | — | US | disclosed |
| EP-1423117-A1 | 2-SUBSTITUTED 1-ARYLPIPERAZINES AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003015784-A1 | 2-SUBSTITUTED 1-ARYLPIPERAZINES AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242592-A1 | 2-Substituted 1-arylpiperazines as tachykinin antagonists and/or serotonin reuptake inhibitors | SLC6A4, TPH1, HTR1D | MEN1 2276/4885KMT2A 1959/4885AGTR2 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.